by Yoshikane Yamauchi, Yotaro Izumi, Masafumi Kawamura, Seishi Nakatsuka, Hideki Yashiro, Norimasa Tsukada, Masanori Inoue, Keisuke Asakura, Hiroaki Nomori
To evaluate the safety and efficacy of cryoablation for metastatic lung tumors from colorectal cancer. Methods
The procedures were performed on 24 patients (36–82 years of age, with a median age of 62; 17 male patients, 7 female patients) for 55 metastatic tumors in the lung, during 30 sessions. The procedural safety, local progression free interval, and overall survival were assessed by follow-up computed tomographic scanning performed every 3–4 months. Results
The major complications were pneumothorax, 19 sessions (63%), pleural effusion, 21 sessions (70%), transient and self-limiting hemoptysis, 13 sessions (43%) and tract seeding, 1 session (3%). The 1- and 3-year local progression free intervals were 90.8% and 59%, respectively. The 3-years local progression free intervals of tumors =15 mm in diameter was 79.8% and that of tumors >15 mm was 28.6% (p?=?0.001; log-rank test). The 1- and 3-year overall survival rates were 91% and 59.6%, respectively. Conclusion
The results indicated that percutaneous cryoablation is a feasible treatment option. The local progression free interval was satisfactory at least for tumors that were =15 mm in diameter.